- 11-50 Employees
- Based in Newark, California
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. MBX-8025 is a potent, selective, orally active PPARδ agonist.
Most Recent Annual Report
2022 Annual Report and Form 10K
CymaBay Therapeutics does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Please fill out the form below and click "Place Order" to complete your order.
Older/Archived Annual Reports